TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17608844

Group type: EXPERIMENTAL
Intervention: 1:10,000 epinephrine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Diluted epinephrine plus normal saline
Number of subjects: 216
Study: 16185377

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale‐15 screening and Montgomery‐Asberg Depression Rating Scale assessment
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Ongoing treatment for depression
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Living in institutions and number of medications
Number of subjects: 242

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 242
Study: 12354212

Group type: EXPERIMENTAL
Intervention: C. albicans positive at baseline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: C. albicans positive post-treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: C. albicans positive at 12 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: C. albicans positive at 24 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: C. albicans positive at 36 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: C. albicans carriage over time
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: C. albicans carriage consistency
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reduction in prevalence from baseline to post-treatment
Number of subjects: 150
Study: 10080203

Group type: EXPERIMENTAL
Intervention: Mechanical debridement
Number of subjects: 278

Group type: COMPARATOR
Intervention: Transepithelial debridement
Number of subjects: 278
Study: 7480473

Group type: EXPERIMENTAL
Intervention: New method for altering Positive Affect, involves completing a boring task for a specific time, with time period adjusted after starting
Number of subjects: 95
Study: 2158410

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Guar gum (5 g three times daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7341065

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Tobramycin Ointment
Number of subjects: 511

Group type: COMPARATOR
Intervention: Gentamicin Sulfate
Number of subjects: 511
Study: 30628857

Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Open Access Technique (OAT)
Number of subjects: 955
Study: 28642210

Group type: EXPERIMENTAL
Intervention: Aspirin 100mg for 1 year
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Clopidogrel 75mg for 1 year
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Aspirin 100mg + PPI for 1 year
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Clopidogrel 75mg + PPI for 1 year
Number of subjects: 1560
Study: 25990828

Group type: EXPERIMENTAL
Intervention: High molecular weight sodium hyaluronate (SH) at a dosage of 9 mg three times a day for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 20
Study: 23683447

Group type: EXPERIMENTAL
Intervention: 40mL of 0.5% lidocaine alone (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of 40mL of 0.25% lidocaine with 0.05mg fentanyl and 0.5mg vecuronium (n=30)
Number of subjects: 60
Study: 21159683

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol administered 3 hours prior to IUD insertion
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo administered 3 hours prior to IUD insertion
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 19002702

Group type: EXPERIMENTAL
Intervention: Bupropion (BUP) 300 mg for 7 days after 150 mg for 3 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 8
Study: 17701883

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (6-8 mg/kg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (euthyroid healthy subjects)
Number of subjects: 44
Study: 15651715

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC in a 50% O2/N2O mixture)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol (8 mg/kg for the first 30 min, followed by 6 mg/kg for maintenance in a 50% O2/N2O mixture)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane (1 MAC in a 50% O2/N2O mixture)
Number of subjects: 60
Study: 11982870

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 86
Study: 10063490

Group type: EXPERIMENTAL
Intervention: mecamylamine (2.5 mg tablet)
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 7586109

Group type: EXPERIMENTAL
Intervention: 22-gauge Sprotte needle (directional, Group 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 22-gauge Quincke needle (non-directional, Group 1)
Number of subjects: 42
Study: 2180995

Group type: EXPERIMENTAL
Intervention: 2% and 3% topical minoxidil
Number of subjects: 31
Study: 759879

Group type: EXPERIMENTAL
Intervention: Penicillamine (600 to 900 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 30891960

Group type: EXPERIMENTAL
Intervention: Pivotal Response Intervention for Social Motivation (PRISM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: community treatment as usual (TAU)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eye tracking (social preference paradigm)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eye tracking (face scanning)
Number of subjects: 28
Study: 28719683

Group type: EXPERIMENTAL
Intervention: Structured Physical Activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Sedentary Lifestyle)
Number of subjects: 0
Study: 26026485

Group type: EXPERIMENTAL
Intervention: 8Gy radiotherapy
Number of subjects: 651

Group type: COMPARATOR
Intervention: 4Gy radiotherapy
Number of subjects: 651
Study: 23506510

Group type: EXPERIMENTAL
Intervention: Single-session brief motivational enhancement (BME) interview
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study: 21219984

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV//PRP‐T combined vaccine (Pentaxim(®))
Number of subjects: 792

Group type: COMPARATOR
Intervention: Individual vaccines (DTaP, PRP‐T, IPV)
Number of subjects: 792
Study: 19320245

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg twice daily) from 28 weeks of gestational age to delivery
Number of subjects: 0
Study: 16626956

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg delivered via Modulite b.i.d.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg dry powder capsules delivered via HandiHaler once daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of Formoterol and Tiotropium
Number of subjects: 21

Group type: COMPARATOR
Intervention: Formoterol alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tiotropium alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: All treatments (Formoterol, Tiotropium, Combination)
Number of subjects: 21
Study: 14517774

Group type: EXPERIMENTAL
Intervention: Daily rhGH therapy (D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alternate-day rhGH therapy (A)
Number of subjects: 20
Study: 10882958

Group type: EXPERIMENTAL
Intervention: Omeprazole and antibiotics for H pylori eradication
Number of subjects: 64

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 64
Study: 8882989

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 60 mg/m2, Carboplatin (CBDCA) 200 mg/m2, Etoposide (VP-16) 100 mg/m2 (Step 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 60 mg/m2, Carboplatin (CBDCA) 250 mg/m2, Etoposide (VP-16) 100 mg/m2 (Step 3)
Number of subjects: 36
Study: 1373366

Group type: EXPERIMENTAL
Intervention: TENS (15 daily 60 min treatments over 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 2994990

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30835327

Group type: EXPERIMENTAL
Intervention: CoQ10 300 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30587642

Group type: EXPERIMENTAL
Intervention: 600 IU Vitamin D3
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 1000 IU Vitamin D3
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D3
Number of subjects: 216
Study: 27406063

Group type: EXPERIMENTAL
Intervention: Rapid Ethical Assessment (REA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 24912581

Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 467

Group type: COMPARATOR
Intervention: Still water
Number of subjects: 467
Study: 22994410

Group type: EXPERIMENTAL
Intervention: Virtual pain coach
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pain communication education only
Number of subjects: 18
Study: 20575111

Group type: EXPERIMENTAL
Intervention: Purse-string closure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional closure
Number of subjects: 61
Study: 18717144

Group type: EXPERIMENTAL
Intervention: CHAMPSA intervention
Number of subjects: 579

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 579
Study: 15987228

Group type: EXPERIMENTAL
Intervention: Adjustable maintenance dosing (one inhalation twice daily, stepping up to four inhalations twice daily for 1 week if asthma worsened)
Number of subjects: 3297

Group type: COMPARATOR
Intervention: Fixed dosing (two inhalations twice daily)
Number of subjects: 3297
Study: 12826844

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.075, 0.15, 0.3, and 0.6 ng/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.15, 0.3, and 0.6 ng/mL)
Number of subjects: 0
Study: 10469307

Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy (wavelength 690 nm, intensity: 80 mW per cm2, dose: 48 J per cm2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (sham-irradiation)
Number of subjects: 50
Study: 8708523

Group type: EXPERIMENTAL
Intervention: Oral lidocaine (50 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg)
Number of subjects: 20
Study: 1789830

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (by mouth or nasogastric tube)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Intravenous rehydration therapy
Number of subjects: 111
Study: 6308488

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 50 mg p.d.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30161206

Group type: EXPERIMENTAL
Intervention: Preconception micronutrient supplementation
Number of subjects: 1409
Study: 26691105

Group type: EXPERIMENTAL
Intervention: Group prenatal care (CenteringPregnancy Plus)
Number of subjects: 1148
Study: 24240647

Group type: EXPERIMENTAL
Intervention: Individualized, moderate-intensity, 12-week home-based exercise program with weekly telephone support from a certified exercise physiologist
Number of subjects: 40
Study: 22339661

Group type: EXPERIMENTAL
Intervention: MVP function programmed [On]
Number of subjects: 220

Group type: COMPARATOR
Intervention: MVP function programmed [off]
Number of subjects: 220
Study: 20150520

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 2327
Study: 18579630

Group type: EXPERIMENTAL
Intervention: Access to the Hearts of Salford health portal
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no access to the health portal)
Number of subjects: 108
Study: 15741848

Group type: EXPERIMENTAL
Intervention: LEAP intervention (Lifestyle Education for Activity Program)
Number of subjects: 2087

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2087
Study: 12186232

Group type: EXPERIMENTAL
Intervention: Variable practice conditions (three different types)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Constant practice condition
Number of subjects: 94
Study: 10100043

Group type: EXPERIMENTAL
Intervention: Pyrophosphate dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 0
Study: 7772916

Group type: EXPERIMENTAL
Intervention: Left intraatrial infusion of prostaglandin E1 (PGE1) at 0.003 microgram/kg/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right intraatrial infusion of prostaglandin E1 (PGE1) at 0.03 microgram/kg/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 30
Study: 2279574

Group type: EXPERIMENTAL
Intervention: Perioperative central haemodynamic monitoring in 21 patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Central venous pressure monitoring alone in 19 patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High risk group (LVEF less than 0.50)
Number of subjects: 40
Study: 7017680

Group type: EXPERIMENTAL
Intervention: ATG (added to azathioprine and prednisolone)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: NSAI drugs (replacing steroids)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (azathioprine and prednisolone without ATG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (steroids)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: ATG group
Number of subjects: 65
Study: 31136093

Group type: EXPERIMENTAL
Intervention: Congenital blindness
Number of subjects: 3138

Group type: COMPARATOR
Intervention: Control group (normal hearing and vision)
Number of subjects: 3138
Study: 27339805

Group type: EXPERIMENTAL
Intervention: Computer-based educational programme
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 226
Study: 25869024

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block (SCPB) with 0.25% bupivacaine, 10 mL
Number of subjects: 46

Group type: COMPARATOR
Intervention: No Block
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block (SCPB)
Number of subjects: 46
Study: 23996765

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at 0.5 µg·kg(‐1)·h(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 60
Study: 21337541

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) 100 mg/kg/day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) moderate levels (0.4-3.2 mM)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) high concentrations (12.5-50 mM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 160
Study: 19675503

Group type: EXPERIMENTAL
Intervention: Resistance training (3 sets of 15RM with 60-second rest between sets and exercises)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 19
Study: 18091655

Group type: EXPERIMENTAL
Intervention: Conservative surgery with sentinel node biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial breast irradiation
Number of subjects: 0
Study: 15129994

Group type: EXPERIMENTAL
Intervention: 5% (w/w) urea in semi-solid emulsions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urea-containing moisturisers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo moisturisers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of SLS-irritated skin with urea and placebo
Number of subjects: 0
Study: 11681814

Group type: EXPERIMENTAL
Intervention: Immunonutrition (including n-3 Polyunsaturated fatty acids, glutamine, arginine, S amino acids, and nucleotides)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunonutrition (n-3 PUFA, glutamine, N-acetyl cysteine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine and nucleotides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 10975536

Group type: EXPERIMENTAL
Intervention: MRI pre-operative localization
Number of subjects: 24

Group type: COMPARATOR
Intervention: CT pre-operative localization
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MRI and CT
Number of subjects: 24
Study: 8766083

Group type: EXPERIMENTAL
Intervention: M-VAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M-CAVI
Number of subjects: 60
Study: 1433586

Group type: EXPERIMENTAL
Intervention: Surgical treatment (Cohen technique in 52% and Politano‐Leadbetter technique in 28%)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 87
Study: 6149128

Group type: EXPERIMENTAL
Intervention: 25 mg carvedilol (invasive study)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 25 mg carvedilol (non-invasive study)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg carvedilol (non-invasive study)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 25 mg carvedilol (all groups)
Number of subjects: 30
Study: 31259819

Group type: EXPERIMENTAL
Intervention: Preoperative MRI for flap tissue planning
Number of subjects: 62

Group type: COMPARATOR
Intervention: External Doppler ultrasonography for flap planning
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of flap raising times and cosmetic outcomes
Number of subjects: 62
Study: 29326067

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 80
Study: 26727684

Group type: EXPERIMENTAL
Intervention: Preoperative stoma marking by a certified wound, ostomy and continence nurse (CWOCN)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No preoperative stoma marking or preoperative ostomy education
Number of subjects: 59
Study: 27366396

Group type: EXPERIMENTAL
Intervention: Esmolol (2 mg kg(‐1) infused over 10 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (50 mL saline infused over 10 min)
Number of subjects: 30
Study: 22194590

Group type: EXPERIMENTAL
Intervention: Peak expiratory flow (PEF) measurement with a pocket spirometer
Number of subjects: 5761

Group type: EXPERIMENTAL
Intervention: Spirometry for those with PEF < 70% predicted
Number of subjects: 5761

Group type: EXPERIMENTAL
Intervention: Spirometry for those with normal PEF
Number of subjects: 5761

Group type: EXPERIMENTAL
Intervention: Risk factor analysis
Number of subjects: 5761

Group type: EXPERIMENTAL
Intervention: Overall screening
Number of subjects: 5761
Study: 20575949

Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 51

Group type: COMPARATOR
Intervention: Unipolar hemiarthroplasty
Number of subjects: 51
Study: 18051009

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) bleaching agent - Opalescence
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) bleaching agent - Opalescence PF (3% potassium nitrate and 0.11% fluoride)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) bleaching agent - Nite White Excel 3 (ACP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) bleaching agent - Opalescence + F (acidulated phosphate fluoride 1.23%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) bleaching agent - Opalescence PF + F
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) bleaching agent - Nite White Excel 3 + F
Number of subjects: 60
Study: 16062097

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 15
Study: 12404706

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10323378

Group type: EXPERIMENTAL
Intervention: Low insulin-ante-hypo (1.5 mU/min x kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High insulin-ante-hypo (15.0 mU/min x kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no antecedent hypoglycemia)
Number of subjects: 30
Study: 8540928

Group type: EXPERIMENTAL
Intervention: Sandoglobulin (SG) (0.5 g/kg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pentaglobin (PG) (5 mL/kg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both IVIG preparations (SG and PG)
Number of subjects: 34
Study: 2185803

Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha‐2a
Number of subjects: 60

Group type: COMPARATOR
Intervention: medroxyprogesterone acetate
Number of subjects: 60
Study: 31585095

Group type: EXPERIMENTAL
Intervention: Human papillomavirus persistence after 1 year
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Human papillomavirus persistence after 3 years
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Colposcopy attendance after 1 year
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Colposcopy attendance after 3 years
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Histopathologically confirmed cervical intraepithelial lesions grade 2 or worse after 1 year
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Histopathologically confirmed cervical intraepithelial lesions grade 2 or worse after 3 years
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Human papillomavirus genotyping
Number of subjects: 405
Study: 31946903

Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 1 ng/ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 3 ng/ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi) of 5 ng/ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Remifentanil effect‐compartment target controlled infusion (Ceremi)
Number of subjects: 26
Study: 28142083

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 54